Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death

Table 2 Synergistic effect of Amygdalin and Sorafenib against HepG2 cell growth after 48 h treatment

	Fraction Affected (Fa)	Dose		CI ^a	DRI ^b
	Fraction Affected (Fa)	Amy (mg/ml)	Sor (µM)	CI ^a	Amy	Sor
Combination	0.5	2.03629	0.40726	0.56644	1.83994	43.5887
	0.75	3.95499	0.79100	0.23784	4.26039	320.631
	0.9	7.68158	1.53632	0.10179	9.86495	2358.51
	0.95	12.0653	2.41307	0.05737	17.4625	9163.72
	0.97	16.6365	3.32730	0.03819	26.2164	24069.5

Dose and effect data were obtained from the MTT assay and were analysed by CompuSyn software. This Table was created using data produced by CompuSyn Report. ^a Combination index (CI) was calculated from the CI equation algorithms using CompuSyn software. CI = 1, < 1 and > 1 indicates additive, synergistic and antagonistic effect, respectively. ^b Dose-reduction index (DRI) was calculated from the DRI equation and algorithm using CompuSyn software. DRI = 1, > 1, and < 1 indicates no, favourable, and not favourable dose-reduction, respectively, for every drug in the corresponding combination

ISSN: 2662-7671